

Matthias Augustin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4323750/publications.pdf>

Version: 2024-02-01

438
papers

16,682
citations

22548

61
h-index

35168

102
g-index

522
all docs

522
docs citations

522
times ranked

9486
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany. <i>Journal of Dermatological Treatment</i> , 2022, 33, 976-982.	1.1	11
2	Exploring determinants of psoriasis patients'™ treatment choices: a discrete-choice experiment study in the United States and Germany. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1511-1520.	1.1	4
3	Development of a model to predict closure of chronic wounds in Germany: Claims data analysis. <i>International Wound Journal</i> , 2022, 19, 76-85.	1.3	4
4	Adherence to Guideline-Oriented Preventive Measures in Patients with Atopic Dermatitis in Germany. <i>Dermatology</i> , 2022, 238, 307-312.	0.9	6
5	Skin Lesions, Skin Care, and Characteristics of Pruritus in Patients Undergoing Haemodialysis. <i>Skin Pharmacology and Physiology</i> , 2022, 35, 87-93.	1.1	3
6	Development and validation of an outcome instrument measuring dry skin – the Xerosis Area and Severity Index (XASI). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
7	Exploring the burden of xerosis cutis and the impact of dermatological skin care from patient's perspective. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2482-2487.	1.1	4
8	Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
9	Psychometric properties of the short version of the Freiburg Life Quality Assessment for chronic venous disease. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 139-145.e1.	0.9	1
10	A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 228-236.	1.3	21
11	Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 413-421.	1.3	8
12	Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
13	Assessment of stigma related to visible skin diseases: a systematic review and evaluation of patient-reported outcome measures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 499-525.	1.3	9
14	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2022, 12, 81-95.	1.4	6
15	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 403-412.	1.3	10
16	How do dermatologists'™ personal models inform a patient-centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast). <i>British Journal of Dermatology</i> , 2022, , .	1.4	2
17	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. <i>British Journal of Dermatology</i> , 2022, 186, 942-954.	1.4	22
18	Effects of workplace skin cancer screenings on preventive and risk behaviour. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 2243-2251.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 573-581.	1.3	4
20	Healthcare Utilization and Treatment Patterns in Patients with Chronic Prurigo and Chronic Pruritus in Germany. Dermatology, 2022, 238, 753-761.	0.9	2
21	Epidemiologie von Hautkrankheiten in Deutschland: systematische Literaturanalyse des aktuellen Forschungsstands " Teil 1: Tumorerkrankungen der Haut. JDDG - Journal of the German Society of Dermatology, 2022, 20, 257-271.	0.4	3
22	S1 Guideline: Diagnosis and therapy of vitiligo. JDDG - Journal of the German Society of Dermatology, 2022, 20, 365-378.	0.4	10
23	Epidemiology of skin diseases in Germany: systematic review of the current state of research " part 1: cutaneous tumor diseases. JDDG - Journal of the German Society of Dermatology, 2022, 20, 257-270.	0.4	7
24	Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR. Journal of Investigative Dermatology, 2022, 142, 2528-2531.e3.	0.3	1
25	Psoriasis comorbidities in Germany: A population-based study on spatiotemporal variations. PLoS ONE, 2022, 17, e0265741.	1.1	6
26	Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey. Dermatology and Therapy, 2022, 12, 1055-1064.	1.4	13
27	Epidemiology of skin diseases in Germany: systematic review of the current state of research " part 3: infectious skin diseases. JDDG - Journal of the German Society of Dermatology, 2022, , .	0.4	0
28	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. British Journal of Dermatology, 2022, 187, 588-589.	1.4	3
29	The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life. International Journal of MS Care, 2022, 24, 147-153.	0.4	1
30	Epidemiology of rosacea in a population-based study of 161,269 German employees. International Journal of Dermatology, 2022, 61, 570-576.	0.5	11
31	Epidemiology of skin diseases in Germany: systematic review of the current state of research " part 2: non-infectious skin diseases. JDDG - Journal of the German Society of Dermatology, 2022, 20, 445-455.	0.4	6
32	Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas. Dermatology and Therapy, 2022, 12, 1121-1131.	1.4	7
33	Epidemiologie von Hautkrankheiten in Deutschland: systematische Literaturanalyse des aktuellen Forschungsstands " Teil 2: nichtinfektiöse Hauterkrankungen. JDDG - Journal of the German Society of Dermatology, 2022, 20, 445-457.	0.4	0
34	Determinants of costs and benefits in atopic dermatitis routine care in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1450-1455.	1.3	3
35	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). British Journal of Dermatology, 2022, 187, 338-352.	1.4	32
36	Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy. Journal of Asthma and Allergy, 2022, Volume 15, 611-621.	1.5	0

#	ARTICLE	IF	CITATIONS
37	New treatments and new assessment instruments for Hidradenitis suppurativa. <i>Experimental Dermatology</i> , 2022, 31, 33-39.	1.4	11
38	Registries, multicentre and genome-wide association studies in hidradenitis suppurativa. <i>Experimental Dermatology</i> , 2022, 31, 22-28.	1.4	1
39	Development and validation of a disease-specific quality of life questionnaire for patients with peripheral artery disease (QOLPAD). <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, .	0.9	0
40	Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the <scp>SERENA</scp> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1796-1804.	1.3	6
41	Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 3-16.	1.3	8
42	Measuring well-being in psoriasis: psychometric properties of the <scp>WHO</scp>â€5 questionnaire. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	2
43	Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). <i>British Journal of Dermatology</i> , 2022, 187, 866-877.	1.4	17
44	The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings. <i>Dermatology and Therapy</i> , 2022, 12, 1711-1727.	1.4	2
45	Patient-physician (dis)agreement on their reports of body surface area affected by psoriasis and its associations with disease burden. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
46	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 123-134.	1.3	25
47	Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. <i>Archives of Dermatological Research</i> , 2021, 313, 95-99.	1.1	11
48	Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 431-440.	1.3	20
49	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study*. <i>British Journal of Dermatology</i> , 2021, 184, 425-436.	1.4	36
50	Determinants of costs and benefits in psoriasis routine care: results from a cross-sectional nationwide study in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e63-e65.	1.3	6
51	The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 738-743.	1.3	25
52	The value of subcutaneous vs. oral methotrexate: real-world data from the German psoriasis registry PsoBest. <i>British Journal of Dermatology</i> , 2021, 184, 765-767.	1.4	8
53	Social participation of people with chronic wounds: A systematic review. <i>International Wound Journal</i> , 2021, 18, 287-311.	1.3	27
54	Validaci3n de la versi3n espa3ola del cuestionario Wound-QoL. <i>Actas Dermo-sifilogrÃficas</i> , 2021, 112, 44-51.	0.2	8

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.	1.4	4
56	A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711.	1.3	13
57	Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 60-69.	0.6	18
58	Epidemiology, Comorbidity and Risk Factors for Psoriatic Arthritis: A Health Insurance Claims Database Analysis. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00566.	0.6	6
59	Validation of the Spanish Wound-QoL Questionnaire. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 44-51.	0.2	3
60	Pruritus Intensity Scales across Europe: a prospective validation study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1176-1185.	1.3	17
61	Assessing the quality of life of people with chronic wounds by using the cross-culturally valid and revised Wound-QoL questionnaire. <i>Wound Repair and Regeneration</i> , 2021, 29, 452-459.	1.5	11
62	Increasing competence in compression therapy for venous leg ulcers through training and exercise measured by a newly developed score—Results of a randomised controlled intervention study. <i>Wound Repair and Regeneration</i> , 2021, 29, 261-269.	1.5	3
63	Stigma in visible skin diseases—a literature review and development of a conceptual model. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1493-1504.	1.3	38
64	Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. <i>JAAD International</i> , 2021, 2, 28-30.	1.1	13
65	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	1.4	40
66	Documenting Patient Data in Psoriasis Clinical Practice—Patient Focus Groups Supporting Psoriasis Experts' Decision-making. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 549-557.	0.8	2
67	Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1553-1561.	1.3	19
68	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. <i>British Journal of Dermatology</i> , 2021, 185, 1160-1168.	1.4	21
69	Quality of psoriasis care in Germany—results from the nationwide health care studies PsoHealth 2004–2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1536-1542.	1.3	18
70	Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1346-1356.	1.3	19
71	Epidemiology of Vitiligo—A Dual Population-Based Approach. <i>Clinical Epidemiology</i> , 2021, Volume 13, 373-382.	1.5	15
72	Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1-11.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases – a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2166-2184.	1.3	18
74	Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1614-1621.	1.3	18
75	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 934-150.	0.4	30
76	The Health Behaviour of German Outpatient Caregivers in Relation to Their Working Conditions: A Qualitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5942.	1.2	6
77	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	1.3	41
78	Determining the Minimal Important Difference for the Wound-QoL Questionnaire. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1571-1578.	0.8	4
79	Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis. <i>Clinical Epidemiology</i> , 2021, Volume 13, 593-602.	1.5	12
80	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1092-1115.	0.4	20
81	Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2270-2276.	1.3	16
82	Measurement properties of patient-reported outcome measures for pruritus: An updated systematic review. <i>Journal of Investigative Dermatology</i> , 2021, , .	0.3	5
83	Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1092-1117.	0.4	18
84	Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2241-2249.	1.3	0
85	Effectiveness of a structured short intervention against stigmatisation in chronic visible skin diseases: Results of a controlled trial in future educators. <i>Health Expectations</i> , 2021, 24, 1790-1800.	1.1	7
86	Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 747-755.	3.3	4
87	The Health Behaviour of German Outpatient Caregivers in Relation to the COVID-19 Pandemic: A Mixed-Methods Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8213.	1.2	5
88	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2398-2408.	1.3	4
89	Network meta-analyses in psoriasis: overview and critical discussion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2367-2376.	1.3	4
90	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021, 38, 5253-5269.	1.3	5

#	ARTICLE	IF	CITATIONS
91	Prevalence and Associated Diseases of Seborrheic Skin in Adults. <i>Clinical Epidemiology</i> , 2021, Volume 13, 845-851.	1.5	3
92	Patient needs and benefits of sublingual immunotherapy for grass pollen-induced allergic rhinitis: an observational study. <i>Immunotherapy</i> , 2021, 13, 1193-1204.	1.0	3
93	Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00403.	0.6	20
94	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2021, 7, 973-979.	1.6	5
95	Status quo and perspectives of dermatology hospitals in Germany: spectra of health care and staff situation. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 14-23.	0.4	2
96	Documentation of psoriasis in routine care – expert consensus on a German data set. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1463-1475.	0.4	8
97	Structures and performance characteristics of dermatology hospitals in Germany. Current status and long-term development. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 5-12.	0.4	2
98	Stationäre Versorgung von Hautkrankheiten in Deutschland: Multi-Source-Analyse zum aktuellen und zukünftigen Bedarf. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 25-54.	0.4	5
99	Strukturen und Leistungsmerkmale der Hautkliniken in Deutschland: Aktuelle Bestandsaufnahme und Langzeitverlauf. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 5-13.	0.4	5
100	Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 25-53.	0.4	19
101	Status quo und Perspektiven der Hautkliniken in Deutschland: Versorgungsspektren und Personalsituation. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 14-24.	0.4	6
102	Population-Based Epidemiologic Study in Venous Diseases in Germany – Prevalence, Comorbidity, and Medical Needs in a Cohort of 19,104 Workers. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 679-687.	1.0	9
103	Regional variations and prevalence of psoriasis in Germany from 2010 to 2017: a cross-sectional, spatio-epidemiological study on ambulatory claims data. <i>BMJ Open</i> , 2021, 11, e047806.	0.8	13
104	Workplace Health Promotion and COVID-19 Support Measures in Outpatient Care Services in Germany: A Quantitative Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12119.	1.2	3
105	The Role of Health Literacy among Outpatient Caregivers during the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11743.	1.2	8
106	A Structured Intervention for Medical Students Significantly Improves Awareness of Stigmatisation in Visible Chronic Skin Diseases: A Randomised Controlled Trial. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00641.	0.6	5
107	Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00660.	0.6	10
108	S2-Guideline for Tele dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, , .	0.4	6

#	ARTICLE	IF	CITATIONS
109	Clinical evaluation of UrgoStart Plus dressings in real-life conditions: results of a prospective multicentre study on 961 patients. <i>Journal of Wound Care</i> , 2021, 30, 966-978.	0.5	1
110	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2020, 6, 935-940.	1.6	7
111	Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 174-179.	1.3	43
112	Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 142-152.	1.3	34
113	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. <i>British Journal of Dermatology</i> , 2020, 182, 869-879.	1.4	31
114	Atopic dermatitis shows significant cutaneous comorbidity: results from large-scale investigations in the working population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 135-141.	1.3	20
115	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1263-1272.	1.3	41
116	Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 310-318.	1.3	25
117	An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12. <i>British Journal of Dermatology</i> , 2020, 183, 52-59.	1.4	2
118	Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1074-1079.	1.3	32
119	Live interactive teledermatology compared to in-person care – a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 733-745.	1.3	32
120	Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for person-centred healthcare of emerging adults and adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1010-1018.	1.3	9
121	Development and psychometric evaluation of the U.S. English Wound-QoL questionnaire to assess health-related quality of life in people with chronic wounds. <i>Wound Repair and Regeneration</i> , 2020, 28, 609-616.	1.5	13
122	Characteristics and determinants of patient burden and needs in the treatment of chronic spontaneous urticaria. <i>European Journal of Dermatology</i> , 2020, 30, 259-266.	0.3	6
123	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.3	10
124	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	1.4	13
125	Perception and determinants of stigmatization of people with psoriasis in the German population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2846-2855.	1.3	19
126	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque Psoriasis treated with Biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	1.3	19

#	ARTICLE	IF	CITATIONS
127	Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. <i>Advances in Therapy</i> , 2020, 37, 2865-2883.	1.3	23
128	Nutritional status and quality of nutrition in chronic wound patients. <i>International Wound Journal</i> , 2020, 17, 1246-1254.	1.3	10
129	National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. <i>BMJ</i> , The, 2020, 369, m1590.	3.0	479
130	Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1666-1671.	1.3	30
131	Influence of human wound exudate on the bactericidal efficacy of antiseptic agents in quantitative suspension tests on the basis of European Standards (DIN EN 13727). <i>International Wound Journal</i> , 2020, 17, 781-789.	1.3	13
132	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	1.1	17
133	Economic evaluation of a tertiary prevention program for occupational skin diseases in Germany. <i>Contact Dermatitis</i> , 2020, 82, 361-369.	0.8	12
134	Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. <i>Journal of Wound Care</i> , 2020, 29, 102-118.	0.5	25
135	Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <sc>TREAT</sc> germany. <i>British Journal of Dermatology</i> , 2020, 183, 382-384.	1.4	37
136	Regional variations in the use of statutory skin cancer screenings in Germany: population-based spatial multisource analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1736-1743.	1.3	7
137	Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 440.	1.2	1
138	Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1174-1185.	1.3	46
139	Relevant Patient Benefit of Sublingual Immunotherapy with Birch Pollen Allergen Extract in Allergic Rhinitis: An Open, Prospective, Non-Interventional Study. <i>Advances in Therapy</i> , 2020, 37, 2932-2945.	1.3	7
140	Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2548-2556.	1.3	10
141	Efficacious psoriasis treatment improves patients' work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e593-e596.	1.3	1
142	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	2.0	169
143	Attitudes towards using electronic health records of patients with psoriasis and dermatologists: a cross-sectional study. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 344.	1.5	3
144	Pharmacoeconomics of Occupational Diseases. , 2020, , 27-36.		0

#	ARTICLE	IF	CITATIONS
145	Lebensqualität. , 2020, , 383-387.		0
146	Gesundheitsökonomie und personenzentrierte Versorgung chronischer Wunden in Deutschland. , 2020, , 419-428.		0
147	Digital Health meets Hamburg integrated medical degree program iMED: concept and introduction of the new interdisciplinary 2 track Digital Health. <i>GMS Journal for Medical Education</i> , 2020, 37, Doc61.	0.1	0
148	Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 41-48.	0.3	5
149	Minimal clinically important difference (<scp>MCID</scp>) for work productivity and activity impairment (<scp>WPAI</scp>) questionnaire in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 318-324.	1.3	26
150	Prevalence, predictors and comorbidity of dry skin in the general population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 147-150.	1.3	72
151	Education in people with venous leg ulcers based on a brochure about compression therapy: A quasi-randomised controlled trial. <i>International Wound Journal</i> , 2019, 16, 1252-1262.	1.3	18
152	S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 856-870.	0.4	18
153	S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 959-973.	0.4	24
154	Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2313-2318.	1.3	2
155	Strategies to reduce stigma related to visible chronic skin diseases: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2029-2038.	1.3	28
156	Translating the <scp>WHA</scp> resolution in a member state: towards a German programme on –Destigmatization– for individuals with visible chronic skin diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2202-2208.	1.3	18
157	Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1633-1643.	1.3	51
158	Cost of illness of melanoma in Europe – a modelling approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 34-45.	1.3	20
159	Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 2019, 181, 976-982.	1.4	22
160	Sunbed use in Europe: Time for information. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-3.	1.3	0
161	Modelling first-year cost of illness of melanoma attributable to sunbed use in Europe. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 46-56.	1.3	4
162	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19

#	ARTICLE	IF	CITATIONS
163	Sunbeds: An international common concern. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 5-5.	1.3	2
164	Validation of a Comprehensive Set of Pruritus Assessment Instruments: The Chronic Pruritus Tools Questionnaire PRURITOOLS. <i>Acta Dermato-Venereologica</i> , 2019, 99, 657-663.	0.6	18
165	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.4	7
166	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 816-827.	1.3	43
167	Topische Therapie bei Psoriasis vulgaris – ein Behandlungspfad. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 3-14.	0.4	31
168	Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees. <i>British Journal of Dermatology</i> , 2019, 181, 743-748.	1.4	30
169	How should electronic health records be designed? A cross-sectional study in patients with psoriasis. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 218.	1.5	7
170	Diagnosis and treatment of xerosis cutis – a position paper. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 3-33.	0.4	64
171	Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 123-127.	1.3	32
172	Review of health economic analyses in atopic dermatitis: how diverse is the literature?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 127-145.	0.7	11
173	Decreasing sunbed use in the German population between 2001 and 2015: survey in 155 679 working persons. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 541-545.	1.3	3
174	Cost of illness of melanoma in Europe – a systematic review of the published literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 504-510.	1.3	23
175	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.4	42
176	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019, 180, 894-901.	1.4	12
177	Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective – Development and validation of a new questionnaire. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 256-261.	0.9	3
178	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled <i>TRANSFIGURE</i> trial. <i>British Journal of Dermatology</i> , 2019, 181, 954-966.	1.4	84
179	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 700-708.	1.3	78
180	Effects of psychosocial interventions on patient-reported outcomes in patients with psoriasis: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2019, 181, 939-945.	1.4	24

#	ARTICLE	IF	CITATIONS
181	S2k-Leitlinie zum Gebrauch von Präparationen zur lokalen Anwendung auf der Haut (Topika). JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.4	12
182	Epidemiology of skin cancer in the German population: impact of socioeconomic and geographic factors. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1906-1913.	1.3	49
183	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology, 2018, 79, 266-276.e5.	0.6	117
184	Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e311-e313.	1.3	4
185	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. British Journal of Dermatology, 2018, 179, 173-181.	1.4	64
186	S2k guidelines for the use of topical preparations on the skin. JDDG - Journal of the German Society of Dermatology, 2018, 16, 376-392.	0.4	18
187	Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1523-1529.	1.3	24
188	Telemedicine in dermatology: findings and experiences worldwide – a systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 215-224.	1.3	143
189	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. Journal of the American Academy of Dermatology, 2018, 78, 741-748.	0.6	22
190	Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 411-419.	1.3	15
191	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1059-1065.	1.3	150
192	Cost of illness of psoriasis – results of a German cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 174-180.	1.3	30
193	Quimp (quality of life impairment): an addition to the quality of life lexicon. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e181-e182.	1.3	28
194	Wound dressings for leg ulcers in Germany: Distribution, regional variations and health care providers. Wound Medicine, 2018, 23, 58-63.	2.7	1
195	Lebensqualität und Behandlungsziele bei Psoriasis aus Patientensicht: Ergebnisse eines österreichweiten Querschnitts-Survey. JDDG - Journal of the German Society of Dermatology, 2018, 16, 981-991.	0.4	0
196	Benefits of a membership in a psoriasis patient organisation: a quasi-experimental longitudinal study. Archives of Dermatological Research, 2018, 310, 807-813.	1.1	4
197	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. British Journal of Dermatology, 2018, 179, 1385-1391.	1.4	25
198	Measurement of healthcare quality in atopic dermatitis – development and application of a set of quality indicators. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2237-2243.	1.3	14

#	ARTICLE	IF	CITATIONS
199	Validation of a short-form of the Freiburg Life Quality Assessment for lymphoedema (FLQA-LS) instrument. <i>British Journal of Dermatology</i> , 2018, 179, 1329-1333.	1.4	13
200	Positionspapier: Diagnostik und Therapie der Xerosis cutis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 3-35.	0.4	21
201	Praxis der Teledermatologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 6-57.	0.4	37
202	How to weight patient-relevant treatment goals for assessing treatment benefit in psoriasis: preference elicitation methods vs. rating scales. <i>Archives of Dermatological Research</i> , 2018, 310, 567-577.	1.1	4
203	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018, 179, 984-986.	1.4	10
204	S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 645-669.	0.4	107
205	Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2191-2199.	1.3	20
206	Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 457-463.e5.	0.6	58
207	Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 981-990.	0.4	8
208	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	6.3	457
209	Was ist Schuppenflechte? - Wahrnehmung und Bewertung der Psoriasis in der deutschen Bevölkerung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 703-710.	0.4	4
210	Fear of cancer progression in patients with stage IA malignant melanoma. <i>European Journal of Cancer Care</i> , 2018, 27, e12901.	0.7	19
211	S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 806-813.	0.4	32
212	What is psoriasis? - Perception and assessment of psoriasis among the German population. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 703-710.	0.4	9
213	Psychosocial Distress of Patients with Psoriasis: Protocol for an Assessment of Care Needs and the Development of a Supportive Intervention. <i>JMIR Research Protocols</i> , 2018, 7, e22.	0.5	11
214	Pharmacoeconomics of Occupational Diseases. , 2018, , 1-10.		0
215	Development and validation of the Patient Benefit Index for peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 219-226.	0.6	4
216	Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data. <i>European Journal of Health Economics</i> , 2017, 18, 181-193.	1.4	4

#	ARTICLE	IF	CITATIONS
217	Epidemiology and use of compression treatment in venous leg ulcers: nationwide claims data analysis in Germany. <i>International Wound Journal</i> , 2017, 14, 338-343.	1.3	42
218	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017, 18, 273-280.	3.3	29
219	Clinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi â€” data from the German CMN registry. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 159-167.	0.4	24
220	Arzneimittelsicherheit bei Psoriasis: Welche Rolle spielt Suizidalit�t?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 353-355.	0.4	1
221	Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1316-1323.	1.3	22
222	Analysis of patients' willingness to be mobile, taking into account individual characteristics and two exemplary indications. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 430-438.	0.4	8
223	Dermatological comorbidity in psoriasis: results from a large-scale cohort of employees. <i>Archives of Dermatological Research</i> , 2017, 309, 349-356.	1.1	19
224	Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 49-59.	0.4	25
225	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017, 177, 1024-1032.	1.4	48
226	Quality of life in patients with primary and secondary lymphedema in the community. <i>Wound Repair and Regeneration</i> , 2017, 25, 466-473.	1.5	15
227	Validity and feasibility of the wound-QoL questionnaire on health-related quality of life in chronic wounds. <i>Wound Repair and Regeneration</i> , 2017, 25, 852-857.	1.5	42
228	Quality-of-life evaluation in chronic wounds: comparative analysis of three disease-specific questionnaires. <i>International Wound Journal</i> , 2017, 14, 1299-1304.	1.3	14
229	Patient-Reported Outcome Measures in Pruritus: A Systematic Review of Measurement Properties. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2069-2077.	0.3	32
230	The Wound-QoL questionnaire on quality of life in chronic wounds is highly reliable. <i>Wound Repair and Regeneration</i> , 2017, 25, 730-732.	1.5	25
231	Perception and image of dermatology in the German general population 2002-2014. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2124-2130.	1.3	16
232	Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. <i>Value in Health</i> , 2017, 20, 1174-1179.	0.1	8
233	Compression therapy â€” cross-sectional observational survey about knowledge and practical treatment of specialised and non-specialised nurses and therapists. <i>International Wound Journal</i> , 2017, 14, 1148-1153.	1.3	37
234	Association of atopy and tentative diagnosis of skin cancer â€” results from occupational skin cancer screenings. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2083-2087.	1.3	11

#	ARTICLE	IF	CITATIONS
235	S2k Guidelines for the diagnosis and treatment of chronic pruritus " update " short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.4	23
236	S2k Leitlinie zur Diagnostik und Therapie des chronischen Pruritus " Update " Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.4	56
237	AB0743...Low rates of major adverse cardiac events, malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for 156 weeks: pooled analysis from the esteeem and palace 1-3 phase 3 trials. , 2017, , .		0
238	Chronic pruritus: evaluation of patient needs and treatment goals with a special regard to differences according to pruritus classification and sex. British Journal of Dermatology, 2017, 176, 363-370.	1.4	29
239	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 294-303.	1.3	12
240	Novel TRPM8 agonist cooling compound against chronic itch: results from a randomized, double-blind, controlled, pilot study in dry skin. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1064-1068.	1.3	42
241	Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 151-157.	1.3	77
242	Dynamic Pruritus Score: Evaluation of the Validity and Reliability of a New Instrument to Assess the Course of Pruritus. Acta Dermato-Venereologica, 2017, 97, 230-234.	0.6	26
243	Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study. Acta Dermato-Venereologica, 2017, 97, 639-641.	0.6	27
244	Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Acta Dermato-Venereologica, 2017, 97, 516-518.	0.6	2
245	Tailoring the Cut-off Values of the Visual Analogue Scale and Numeric Rating Scale in Itch Assessment. Acta Dermato-Venereologica, 2017, 97, 759-760.	0.6	65
246	Epidemiology of chronic wounds in Germany: Analysis of statutory health insurance data. Wound Repair and Regeneration, 2016, 24, 434-442.	1.5	170
247	Barriers to guideline-compliant psoriasis care: analyses and concepts. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 569-575.	1.3	38
248	Differences in patient and physician assessment of a dynamic patient reported outcome tool for chronic pruritus. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 962-965.	1.3	6
249	Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. International Journal of Dermatology, 2016, 55, 296-302.	0.5	45
250	Participation and health care provision of statutory skin cancer screening in Germany " a secondary data analysis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 424-427.	1.3	17
251	Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response " results of a phase II regimen-finding trial. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 645-649.	1.3	18
252	Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. Dermatology, 2016, 232, 640-647.	0.9	32

#	ARTICLE	IF	CITATIONS
253	FRIO460â€¦Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 603.2-604.	0.5	9
254	Compression therapy â€œ current practice of care: level of knowledge in patients with venous leg ulcers. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1273-1282.	0.4	10
255	Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA realâ€world study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1270.	0.4	10
256	Der Einfluss von Alitretinoin auf die LebensqualitÃt bei Patienten mit schwerem chronischen Handekzem: FUGETTA â€Beobachtungsstudie unter Praxisbedingungen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1261-1272.	0.4	6
257	Cost-Effectiveness of Secukinumab as First Biologic Treatment for Psoriasis Compared with Initiating Other Biologic Therapy in Germany. <i>Value in Health</i> , 2016, 19, A568-A569.	0.1	2
258	Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry. <i>Dermatology</i> , 2016, 232, 655-663.	0.9	18
259	Quality of psoriasis care in Germany: results of the national health care study â€œPsoHealth3â€ Archives of Dermatological Research, 2016, 308, 401-408.	1.1	41
260	Development and validation of the Patient Benefit Index for the dermatocosmetic treatment of aged skin. <i>Archives of Dermatological Research</i> , 2016, 308, 319-324.	1.1	3
261	Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. <i>Dermatology</i> , 2016, 232, 334-343.	0.9	12
262	The German National Program on Psoriasis Health Care 2005â€2015: results and experiences. <i>Archives of Dermatological Research</i> , 2016, 308, 389-400.	1.1	47
263	Tofacitinib improves pruritus and health-related quality of life up to 52Ãweeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	0.6	57
264	Patient benefits in the treatment of psoriasis: longâ€term outcomes in German routine care 2007â€2014. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1829-1833.	1.3	9
265	Promoting patientâ€centred care in psoriatic arthritis: a multidisciplinary <sc>E</sc>uropean perspective on improving the patient experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 576-585.	1.3	62
266	S2k guideline on diagnosis and treatment of atopic dermatitis â€œ short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 92-105.	0.4	49
267	Ustekinumab in der Therapie der Pustulosis palmoplantaris â€œ Eine Fallserie mit neun Patienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1109-1115.	0.4	4
268	Ustekinumab in the treatment of palmoplantar pustular psoriasis â€œ a case series of nine patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1108-1113.	0.4	19
269	Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. <i>Journal of Dermatological Treatment</i> , 2016, 27, 577-583.	1.1	19
270	Health economic analyses of psoriasis management: a systematic literature search. <i>Archives of Dermatological Research</i> , 2016, 308, 601-616.	1.1	20

#	ARTICLE	IF	CITATIONS
271	Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1148-1158.	1.3	209
272	A systematic review on methods used to evaluate patient preferences in psoriasis treatments. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1454-1464.	1.3	29
273	Kompressionstherapie "Versorgungspraxis: Informationsstand von Patienten mit Ulcus cruris venosum. JDDG - Journal of the German Society of Dermatology, 2016, 14, 1273-1283.	0.4	20
274	European EADV network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1144-1147.	1.3	41
275	S2k guideline on diagnosis and treatment of atopic dermatitis " short version. Allergo Journal International, 2016, 25, 82-95.	0.9	60
276	Psoriasis registries worldwide: systematic overview on registry publications. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1100-1106.	1.3	35
277	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	2.7	47
278	Quality of life in psoriasis. , 2016, , 101-116.		2
279	Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. American Journal of Clinical Dermatology, 2016, 17, 163-169.	3.3	77
280	Cost-effectiveness of treating vascular leg ulcers with UrgoStart [®] and UrgoCell [®] Contact. International Wound Journal, 2016, 13, 82-87.	1.3	27
281	Patient-relevant treatment goals in psoriasis. Archives of Dermatological Research, 2016, 308, 69-78.	1.1	92
282	Patient-relevant needs and treatment goals in nail psoriasis. Quality of Life Research, 2016, 25, 1179-1188.	1.5	16
283	The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach. Quality of Life Research, 2016, 25, 447-455.	1.5	6
284	Patient Needs and Treatment Goals in Clinical Care of Chronic Pruritus. , 2016, , 111-116.		1
285	Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 674-689.	0.4	50
286	Stellenwert der Basistherapie bei Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 415-418.	0.4	6
287	Arbeitsgemeinschaft Dermatologische Onkologie (ADO). JDDG - Journal of the German Society of Dermatology, 2015, 13, 730-731.	0.4	1
288	Waiting time and practice organization in dermatology. JDDG - Journal of the German Society of Dermatology, 2015, 13, 812-814.	0.4	20

#	ARTICLE	IF	CITATIONS
289	Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?. British Journal of Dermatology, 2015, 172, 1669-1671.	1.4	25
290	Fr¼herkennung der KomorbiditÄt bei Psoriasis: Konsensusempfehlungen der Nationalen Konferenz zur Versorgung der Psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 674-690.	0.4	19
291	Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology, 2015, 231, 35-40.	0.9	126
292	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Archives of Dermatological Research, 2015, 307, 875-883.	1.1	124
293	Treatment goals in psoriasis routine care. Archives of Dermatological Research, 2015, 307, 445-449.	1.1	29
294	Clinical management of pruritus. JDDG - Journal of the German Society of Dermatology, 2015, 13, 101-114.	0.4	12
295	Measuring Change in Quality of Life: Bias in Prospective and Retrospective Evaluation. Value in Health, 2015, 18, 110-115.	0.1	177
296	Patient-reported outcomes as diagnostic tools and clues in chronic wounds: Considerations for practice. Wound Medicine, 2015, 8, 6-14.	2.7	8
297	Importance of basic therapy in psoriasis. JDDG - Journal of the German Society of Dermatology, 2015, 13, 415-418.	0.4	16
298	Ingenol mebutate gel for actinic keratosis: The link between quality of life, treatment satisfaction, and clinical outcomes. Journal of the American Academy of Dermatology, 2015, 72, 816-821.	0.6	31
299	Quality of life in psoriasis patients. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 559-568.	0.7	88
300	German psoriasis registry PsoBest: objectives, methodology and baseline data. JDDG - Journal of the German Society of Dermatology, 2014, 12, 48-57.	0.4	63
301	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. British Journal of Dermatology, 2014, 170, 591-598.	1.4	51
302	Biosimilars in psoriasis: What can we expect?. JDDG - Journal of the German Society of Dermatology, 2014, 12, 306-312.	0.4	13
303	The "Wound" QoL. A short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair and Regeneration, 2014, 22, 504-514.	1.5	125
304	Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 719-726.	1.3	45
305	Compression therapy: scientific background and practical applications. JDDG - Journal of the German Society of Dermatology, 2014, 12, 794-801.	0.4	54
306	Topical long-term therapy of psoriasis with vitamin D ₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. JDDG - Journal of the German Society of Dermatology, 2014, 12, 667-682.	0.4	29

#	ARTICLE	IF	CITATIONS
307	Use of the WoundQoL instrument in routine practice: Feasibility, validity and development of an implementation tool. <i>Wound Medicine</i> , 2014, 5, 4-8.	2.7	37
308	Evaluation of Patient-relevant Outcomes of Lymphedema and Lipedema Treatment: Development and Validation of a New Benefit Tool. <i>European Journal of Vascular and Endovascular Surgery</i> , 2014, 47, 100-107.	0.8	31
309	Willingness to pay and quality of life in patients with atopic dermatitis. <i>Archives of Dermatological Research</i> , 2014, 306, 279-286.	1.1	96
310	Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 803-811.	0.4	16
311	Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 309-313.	1.3	96
312	Randomized standard-of-care-controlled trial of a silica gel fibre matrix in the treatment of chronic venous leg ulcers. <i>European Journal of Dermatology</i> , 2014, 24, 210-216.	0.3	11
313	The Definition and Role of Quality of Life In Germany's Early Assessment of Drug Benefit. <i>Value in Health</i> , 2014, 17, A444.	0.1	1
314	Measuring Change in Quality of Life: Can We Distinguish Recall Bias and Scale Recalibration?. <i>Value in Health</i> , 2014, 17, A575.	0.1	1
315	Methodological Requirements Regarding Quality of Life Measurement in the Early Assessment of Benefit In Germany. <i>Value in Health</i> , 2014, 17, A437.	0.1	1
316	Methods Used To Measure Patient Preferences In Psoriasis Treatments – An Overview With Regards To The German Iqwig And G-Ba. <i>Value in Health</i> , 2014, 17, A574.	0.1	0
317	Comparative Effectiveness of An Acellular Synthetic Matrix As An Adjunct to Standard Care In The Treatment of Venous And Mixed Leg Ulcers: Modeling of Clinical Data And Routine Data. <i>Value in Health</i> , 2014, 17, A604.	0.1	1
318	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 171, 1123-1128.	1.4	120
319	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <sc>TRANSIT</sc> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.4	37
320	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.4	24
321	Quality of life measurement in chronic wounds and inflammatory skin diseases: Definitions, standards and instruments. <i>Wound Medicine</i> , 2014, 5, 29-38.	2.7	16
322	Loss of Interface Pressure in Various Compression Bandage Systems over Seven Days. <i>Dermatology</i> , 2014, 229, 343-352.	0.9	31
323	Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study – Atopic Health'. <i>Dermatology</i> , 2014, 228, 350-359.	0.9	20
324	Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 48-58.	0.4	29

#	ARTICLE	IF	CITATIONS
325	The German national consensus on wound documentation and outcomes: Rationale, working programme and current status. <i>Wound Medicine</i> , 2014, 7, 8-13.	2.7	7
326	Cost-of-illness of leg ulcers in the community. <i>International Wound Journal</i> , 2014, 11, 283-292.	1.3	112
327	Validation of the disease-specific quality of life Wuerzburg Wound Score in patients with chronic leg ulcer. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 372-379.	0.6	19
328	Influence of learning disabilities on the tumour predisposition syndrome NF1--survey from adult patients' perspective. <i>Anticancer Research</i> , 2014, 34, 3675-81.	0.5	7
329	Development and use of guideline-derived quality indicators for community lymphoedema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 227-234.	1.3	8
330	Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. <i>Archives of Dermatological Research</i> , 2013, 305, 197-204.	1.1	24
331	Cumulative Life Course Impairment (CLCI): A new concept to characterize persistent patient burden in chronic wounds. <i>Wound Medicine</i> , 2013, 1, 2-6.	2.7	13
332	Effectiveness of Advanced versus Conventional Wound Dressings on Healing of Chronic Wounds: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2013, 226, 172-184.	0.9	85
333	Influenza vaccination rate among patients with moderate to severe psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 837-844.	0.4	12
334	Cumulative Life Course Impairment in Chronic Wounds. <i>Current Problems in Dermatology</i> , 2013, 44, 125-129.	0.8	10
335	Prevalence and Disease Burden of Hyperhidrosis in the Adult Population. <i>Dermatology</i> , 2013, 227, 10-13.	0.9	76
336	Cost-of-illness Analysis of Patients with Chronic Hand Eczema in Routine Care in Germany: Focus on the Impact of Occupational Disease. <i>Acta Dermato-Venereologica</i> , 2013, 93, 538-543.	0.6	38
337	Pruritus Assessment in Clinical Trials: Consensus Recommendations from the International Forum for the Study of Itch (IFSI) Special Interest Group Scoring Itch in Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2013, 93, 509-514.	0.6	141
338	Drug supply for children with psoriasis in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.4	12
339	Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1195-1203.	1.3	67
340	Drug supply for psoriasis -- results from a national pharmacy network. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 638-643.	0.4	8
341	Nail psoriasis -- a treatment challenge. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 203-220.	0.4	18
342	Making proper judgement when choosing a treatment for actinic keratosis. <i>Expert Review of Dermatology</i> , 2013, 8, 595-603.	0.3	2

#	ARTICLE	IF	CITATIONS
343	Quality of Care of Patients with Chronic Lymphoedema in Germany. <i>Dermatology</i> , 2013, 226, 238-246.	0.9	9
344	Cumulative Life Course Impairment: Identifying Patients at Risk. <i>Current Problems in Dermatology</i> , 2013, 44, 74-81.	0.8	22
345	Leistungsprofile der Deutschen Universitäts-Hautkliniken. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 170-177.	0.4	9
346	Allergies in Germany – prevalence and perception by the public. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 514-520.	0.4	20
347	Patient Benefit Index (PBI) in the treatment of psoriasis – results of the National Care Study – PsoHealth. <i>European Journal of Dermatology</i> , 2013, 23, 212-217.	0.3	18
348	Lymphedema - the long way to diagnosis and therapy. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 363-369.	0.6	9
349	Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus. <i>Acta Dermato-Venereologica</i> , 2012, 92, 502-507.	0.6	379
350	Visual Analogue Scale: Evaluation of the Instrument for the Assessment of Pruritus. <i>Acta Dermato-Venereologica</i> , 2012, 92, 497-501.	0.6	347
351	Routine Skin Cancer Screening in Germany: Four Years of Experience from the Dermatologists' Perspective. <i>Dermatology</i> , 2012, 225, 289-293.	0.9	10
352	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. <i>Dermatology</i> , 2012, 224, 236-243.	0.9	43
353	Chronic venous leg ulcers: the future of cell-based therapies. <i>Lancet, The</i> , 2012, 380, 953-955.	6.3	15
354	Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 433-441.	1.1	66
355	Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. <i>Current Dermatology Reports</i> , 2012, 1, 148-159.	1.1	27
356	Quality of care for leg ulcers in the metropolitan area of Hamburg – a community-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 495-502.	1.3	33
357	Benefit evaluation in the therapy of chronic wounds from the patients' perspective – development and validation of a new method. <i>Wound Repair and Regeneration</i> , 2012, 20, 8-14.	1.5	34
358	Skin cancer screening in Germany - perception by the public. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 42-49.	0.4	28
359	Gesetzliches Hautkrebscreening in Deutschland: Wahrnehmung in der Öffentlichkeit. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 42-50.	0.4	18
360	Processes of psoriasis health care in Germany – long-term analysis of data from the statutory health insurances. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 648-655.	0.4	27

#	ARTICLE	IF	CITATIONS
361	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG - Journal of the German Society of Dermatology, 2012, 10, S1-95.	0.4	235
362	A framework for improving the quality of care for people with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1-16.	1.3	42
363	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.1	96
364	Pharmacoeconomics of Occupational Diseases. , 2012, , 19-26.		2
365	PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal of Drugs in Dermatology, 2012, 11, 1210-7.	0.4	63
366	Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcome Measures, 2011, 2, 1.	0.7	38
367	Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. Journal of Dermatological Treatment, 2011, 22, 337-347.	1.1	44
368	A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 665-670.	2.7	21
369	Cost of illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. British Journal of Dermatology, 2011, 165, 845-851.	1.4	47
370	Prevalence of skin lesions and need for treatment in a cohort of 90880 workers. British Journal of Dermatology, 2011, 165, 865-873.	1.4	166
371	The impact of oral vitamin A derivatives on lipid metabolism " What recommendations can be derived for dealing with this issue in the daily dermatological practice?. JDDG - Journal of the German Society of Dermatology, 2011, 9, 600-606.	0.4	18
372	Therapy of psoriasis in childhood and adolescence " a German expert consensus. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-823.	0.4	32
373	Therapie der Psoriasis im Kindes- und Jugendalter - ein deutscher Experten-Konsens. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-824.	0.4	29
374	Systemic treatment with corticosteroids in psoriasis " health care provision far beyond the S3-guidelines. JDDG - Journal of the German Society of Dermatology, 2011, 9, 833-838.	0.4	26
375	Systemische Glukokortikosteroide bei Psoriasis - Versorgung jenseits der S3-Leitlinie. JDDG - Journal of the German Society of Dermatology, 2011, 9, 833-839.	0.4	17
376	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. JDDG - Journal of the German Society of Dermatology, 2011, 9, S1-S95.	0.4	66
377	Dimensions of patient needs in dermatology: subscales of the patient benefit index. Archives of Dermatological Research, 2011, 303, 11-17.	1.1	53
378	Adherence in the Treatment of Psoriasis: A Systematic Review. Dermatology, 2011, 222, 363-374.	0.9	146

#	ARTICLE	IF	CITATIONS
379	Efficacy, Tolerability and Patient Benefit of Ultrasound-Assisted Wound Treatment versus Surgical Debridement: A Randomized Clinical Study. <i>Dermatology</i> , 2011, 222, 244-249.	0.9	46
380	Quality of Care in Chronic Leg Ulcer in the Community: Introduction of Quality Indicators and a Scoring System. <i>Dermatology</i> , 2011, 222, 321-329.	0.9	42
381	Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis. <i>Dermatology</i> , 2011, 223, 80-86.	0.9	20
382	Quality of life and satisfaction of patients with leg ulcers - results of a community-based study. <i>Vasa - European Journal of Vascular Medicine</i> , 2011, 40, 131-138.	0.6	57
383	Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. <i>European Journal of Dermatology</i> , 2010, 20, 062-067.	0.3	88
384	Internet-supported gathering of treatment data and patient benefits in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 541-547.	1.3	6
385	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 989-1004.	1.3	180
386	How do regional factors influence psoriasis patient care in Germany?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 516-523.	0.4	18
387	Welchen Einfluss haben regionale Faktoren auf die Versorgung der Psoriasis in Deutschland?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 516-524.	0.4	12
388	Routine skin cancer screening in Germany: First data on the impact on health care in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 674-680.	0.4	11
389	Das Hautkrebscreening als Regelleistung der gesetzlichen Krankenkassen: Erste Daten zu den Auswirkungen auf die dermatologische Versorgung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 674-680.	0.4	8
390	Cost of illness of chronic leg ulcers in Germany. <i>International Wound Journal</i> , 2010, 7, 97-102.	1.3	165
391	Quality of life evaluation in wounds: validation of the Freiburg Life Quality Assessment wound module, a disease-specific instrument. <i>International Wound Journal</i> , 2010, 7, 493-501.	1.3	59
392	Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. <i>British Journal of Dermatology</i> , 2010, 162, 661-668.	1.4	108
393	Epidemiology and comorbidity of psoriasis in children. <i>British Journal of Dermatology</i> , 2010, 162, 633-636.	1.4	375
394	Nail psoriasis in Germany: epidemiology and burden of disease. <i>British Journal of Dermatology</i> , 2010, 163, 580-585.	1.4	160
395	Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2010, 221, 236-242.	0.9	21
396	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. <i>Acta Dermato-Venereologica</i> , 2010, 90, 147-151.	0.6	265

#	ARTICLE	IF	CITATIONS
397	Prevalence of Chronic Pruritus in Germany: Results of a Cross-Sectional Study in a Sample Working Population of 11,730. <i>Dermatology</i> , 2010, 221, 229-235.	0.9	165
398	Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis. <i>Dermatology</i> , 2010, 221, 154-159.	0.9	53
399	Methods of Outcomes Measurement in Nail Psoriasis. <i>Dermatology</i> , 2010, 221, 23-28.	0.9	67
400	Double-Blind, Randomized, Intraindividual Comparison Study of the Efficacy of Prilocaine and Lidocaine in Tumescant Local Anesthesia. <i>Dermatology</i> , 2010, 221, 248-252.	0.9	28
401	Clinical Features and Treatment Outcomes of Vitiligo from the Patients' Perspective: Results of a National Survey in Germany. <i>Dermatology</i> , 2010, 220, 194-200.	0.9	21
402	Assessing the Value of Supportive Skin Care: Development and Validation of an Instrument for Evaluating Patient-Relevant Benefit. <i>Dermatology</i> , 2009, 218, 255-259.	0.9	18
403	Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. <i>Dermatology</i> , 2009, 219, 54-58.	0.9	42
404	Health Services Research in Psoriasis – The German Approach. <i>Dermatology</i> , 2009, 218, 293-301.	0.9	17
405	The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. <i>Archives of Dermatological Research</i> , 2009, 301, 561-571.	1.1	151
406	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1040-1047.	1.4	341
407	Willingness-to-pay and quality of life in patients with vitiligo. <i>British Journal of Dermatology</i> , 2009, 161, 134-139.	1.4	135
408	Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. <i>British Journal of Dermatology</i> , 2009, 161, 1143-1148.	1.4	71
409	Quality of medical care of patients with acne vulgaris in Germany – nationwide survey of pharmacy clients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1060-1063.	0.4	11
410	Versorgung der Akne vulgaris in Deutschland – Patientenbefragung in einem bundesweiten Apothekennetzwerk. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 1060-1064.	0.4	12
411	Measurement of patient-relevant benefits in the treatment of chronic hand eczema – a novel approach. <i>Contact Dermatitis</i> , 2009, 61, 39-45.	0.8	29
412	Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 292-299.	1.3	21
413	Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 683-691.	1.3	159
414	Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 113-120.	0.4	27

#	ARTICLE	IF	CITATIONS
415	Does climate change affect the incidence of skin and allergic diseases in Germany?. JDDG - Journal of the German Society of Dermatology, 2008, 6, 632-638.	0.4	10
416	Quality of psoriasis care in Germany – results of the national study PsoHealth 2007. JDDG - Journal of the German Society of Dermatology, 2008, 6, 640-645.	0.4	63
417	Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 1560-1561.	2.7	14
418	Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany. Dermatology, 2008, 216, 366-372.	0.9	237
419	Prevalence of Skin Diseases in a Cohort of 48,665 Employees in Germany. Dermatology, 2008, 217, 169-172.	0.9	141
420	Benefit Evaluation in Vitiligo Treatment: Development and Validation of a Patient-Defined Outcome Questionnaire. Dermatology, 2008, 217, 101-106.	0.9	35
421	Cost-Effectiveness Model of Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Germany. Dermatology, 2007, 215, 219-228.	0.9	26
422	Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients. Journal of Investigative Dermatology, 2007, 127, 2315-2322.	0.3	80
423	Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multi-center study. JDDG - Journal of the German Society of Dermatology, 2007, 5, 209-218.	0.4	87
424	Health services research in dermatology ? current update and perspectives. JDDG - Journal of the German Society of Dermatology, 2007, 5, 482-487.	0.4	6
425	Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. JDDG - Journal of the German Society of Dermatology, 2007, 5, 1-119.	0.4	104
426	Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. Dermatology, 2006, 212, 137-144.	0.9	109
427	Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. Krankheitskosten bei Patienten mit mittelschwerer und schwerer chronischer Psoriasis vulgaris in Deutschland. JDDG - Journal of the German Society of Dermatology, 2005, 3, 511-518.	0.4	92
428	Policy decision making and outcomes research in drug utilization. Zeitschrift Fur Gesundheitswissenschaften, 2005, 13, 257-264.	0.8	3
429	Development, validation and clinical use of the FLQA-I, a disease-specific quality of life questionnaire for patients with lymphedema. Vasa - European Journal of Vascular Medicine, 2005, 34, 31-35.	0.6	52
430	German Adaptation of the Skindex-29 Questionnaire on Quality of Life in Dermatology: Validation and Clinical Results. Dermatology, 2004, 209, 14-20.	0.9	70
431	Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. European Journal of Dermatology, 2004, 14, 107-113.	0.3	35
432	Quality of Life in Different Stages of Chronic Venous Insufficiency and Leg Ulcer. Dermatology and Psychosomatics, 2002, 3, 126-131.	0.1	14

#	ARTICLE	IF	CITATIONS
433	Effects of Autologous Keratinocyte Transplantation on the Quality of Life of Patients with Severe Chronic Leg Ulcers. <i>Dermatology and Psychosomatics</i> , 2001, 2, 73-76.	0.1	11
434	Predictors of the Quality of Life in Patients with Atopic Dermatitis. <i>Dermatology and Psychosomatics</i> , 2000, 1, 66-70.	0.1	16
435	Validation and Clinical Results of the FLQA-d, a Quality of Life Questionnaire for Patients with Chronic Skin Disease. <i>Dermatology and Psychosomatics</i> , 2000, 1, 12-17.	0.1	62
436	Attitudes and Experiences towards Corticoid Treatment among Parents of Children with Atopic Dermatitis. <i>Dermatology and Psychosomatics</i> , 2000, 1, 155-161.	0.1	6
437	Development and validation of a disease-specific questionnaire on the quality of life of patients with chronic venous insufficiency. <i>Vasa - European Journal of Vascular Medicine</i> , 1997, 26, 291-301.	0.6	58
438	Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. <i>Skin Health and Disease</i> , 0, , .	0.7	2